GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo
- 22 October 2020
- journal article
- research article
- Published by Elsevier in Neurochemistry International
- Vol. 141, 104889
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81671668)
- National Natural Science Foundation of China (81371534)
- National Institutes of Health (R01 EB016089)
- National Institutes of Health (R01 EB023693)
- National Institutes of Health (P41 EB015909)
This publication has 41 references indexed in Scilit:
- An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generationNeurological Sciences, 2013
- GABA-A Channel Subunit Expression in Human Glioma Correlates with Tumor Histology and Clinical OutcomePLOS ONE, 2012
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomideNeurology, 2009
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- Malignant Gliomas in AdultsNew England Journal of Medicine, 2008
- Resveratrol Induces Apoptosis through ROS-Dependent Mitochondria Pathway in HT-29 Human Colorectal Carcinoma CellsJournal of Agricultural and Food Chemistry, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Quantitative analysis of glutathione in human brain tumorsJournal of Neurosurgery, 1990